{"name":"NMD Pharma A/S","slug":"nmd-pharma-a-s","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQRHJtakxvdkRYZ3J2azgyVWJiMVJpdDNZSFBQbEFfakVCcjZ0dUsydlVOMTlxa2pFdUdVengtendsdmJ2UG9nYzB5aVBJc1pYMmJwbnVkeTdlZ0xEMDRVVVBrYnFrN1lsNmo4VGlKdkdCSnV0c3VkdzlmRFluXzgtbmVNQURBNFpKa00tZDlWeXBod3hLR3ExTmpLbUxRTGFkMThDV0FmMk54VHJpeEhWbzRoSEhXVUlsYi1Ca2QyV3dPbWxvV0ZqMGFqbnN4Rk5Wd3N6ZUZ0dVR1MGpMdzF6eFhLN1l2a1MxbnFock1VU0ZMY0RHRTBHUmVB?oc=5","date":"2026-04-02","type":"trial","source":"Barchart.com","summary":"Motor Neuron Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveInsight - Barchart.com","headline":"Motor Neuron Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPZzhzNUV4V0FldDBxX1FvMzZhOEJoTzdlbUxyb3Jpc3dIMDFsX3NrM2ZIc1NNLTBKR0dmcVZ4ZmotRWREY0RVdEZ4ZXY2Z2h2X29aMGMwbHcyVUlDSV9JakU0YTdmSWFHdE1sOUxhR3Q3M2swa3V3cy05dEtUbHA0OTdPMVBac2ZBMWZ6dTMwT0x0RmN2NHc?oc=5","date":"2026-04-01","type":"pipeline","source":"openPR.com","summary":"Charcot-Marie-Tooth (CMT) Disease Market Size to Reach US$ - openPR.com","headline":"Charcot-Marie-Tooth (CMT) Disease Market Size to Reach US$","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-10","type":"trial","source":"The Manila Times","summary":"NMD Pharma late breaking oral presentation at the MDA Conference with top-line safety and efficacy data from SYNAPSE-CMT, an exploratory Phase 2a clinical study of ignaseclant in Charcot-Marie-Tooth d","headline":"NMD Pharma late breaking oral presentation at the MDA Conference with top-line safety and efficacy data from SYNAPSE-CMT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxPRGpDUVlZMVdhR1I5S1hKTXBHY1hnM2UxZk11SWtIYktMZlpDNWw3Zkt5M2EzajQ3eU9LUmZ0N2Q3N1BDZ1RDSUU1Vm5tX3hVVlpUWmhRNkF0MUFZaGVOWkN1U2hRWmxzOXZUcVNRMmZpWTQ2b2FSejFwSUtfTWVaU3lJUkU3NDBtUnlTUnlrZy1DZ2pnd0JlN2NHbmFidUoxWWF2N25jbFdpb1QwcDZtSEJ4VE5uRDFvVXQ0bDBCWmlGR1FiRjFDRFZKWWlyc0JBNHFEaW1teXphUlYwcVJyaE9LaU1yYWtIWWMzb2ZleWZDd1RxX2x0RTdkLWFUa19iZGtrRk03ZVhKS0xQUXFEZngwUGtfbGhlYU9iMg?oc=5","date":"2026-02-03","type":"trial","source":"GlobeNewswire","summary":"NMD Pharma announces topline results from its Phase 2a - GlobeNewswire","headline":"NMD Pharma announces topline results from its Phase 2a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPdzQ1YzFzQ2hfWHlMczNINFRVSVJldXVMOXg3dWF2aVZMMzktRjRxNlJvY0k0MEFtNDJxRW1SWm1ESWd1cWI3U1dXNS1kS2dDZnBEZXJNMTNaVHYwaElja3NVd280T1JRNGtuWWVXZGZIQ3RJVmlwMlRmWjVHSXZkd0IyODQwR3RVQmZuRjl3YkJFZXJBV2hISTVjNG82UFk?oc=5","date":"2026-02-03","type":"trial","source":"BioWorld News","summary":"NMD reports positive phase II data in Charcot-Marie-Tooth - BioWorld News","headline":"NMD reports positive phase II data in Charcot-Marie-Tooth","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQdWtFYWh1NHhuQ1E2VWRiZXpEUTNfd2R2bC1VbkZ5Q2tMYjdBY3ZyNmFEMUJaVUxEZ2lxbVQzTGYydGtEMDlRQWpfX2toRnRmUW96TFE4QUhGcVVtZlc4M0FqNjZndU9ZeG5MRHBqeGFKM1Z2NlZ6S2JfY3RKZ1R1Z0dPX05Edi0xM2E2QVp4cWF6VXlTSjVlVXVsMk8xODFEZ1ZMLTRvbUM0QW5ubkF3aGRQMkNmbzZ1RTc4cEc2SjBSWmhSQ2JzNGdtRENxNEFka0EwcGVWY082eHJrdGc?oc=5","date":"2026-01-06","type":"pipeline","source":"GlobeNewswire","summary":"NMD Pharma to present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire","headline":"NMD Pharma to present at the 44th Annual J.P. Morgan Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPZTM3V3kxM1M5QUZ0WjVfaXNMTTJOVFBjY2g0RXdsR3FMVHF3bFdIb0ZjSzR2cnc1enVKVF9nYXF5QUVjaWYyWVlxZTVVYkxQVWxaLTZhYkx4Nk9PeE1PZDN3TUlwVkc0OEVlLU5XcG9uMnotQ1JRWEJTUWFfNm1STUl3dkRZRVNWOUJzdHZaQnZMdGVPOGloUTh5SlV5OGRPZFF5RUprTkFCRVFHYkE?oc=5","date":"2025-09-23","type":"pipeline","source":"BioWorld News","summary":"Another Catalent Indiana delay: Scholar Rock gets CRL for apitegromab - BioWorld News","headline":"Another Catalent Indiana delay: Scholar Rock gets CRL for apitegromab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNR0MyS1R2aTZJakNwTHZoT3ZiQlpVTFR6UVhLaG9PN3BlUnNWMmJncW9lM0ZXcW5Ra2NTeUpJSFhrUk5ORU5kR05lV3pDX1h4Z1Z2NS1QODRjX0huZmx2RFBYUWd1SzBxczRGdllsLThNQjN3eGR4WVNTWWJobHBhREhtU0ZsX1AwUlE?oc=5","date":"2024-03-22","type":"pipeline","source":"European Biotechnology Magazine","summary":"NDM Pharma provides POC for NMD670 - European Biotechnology Magazine","headline":"NDM Pharma provides POC for NMD670","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTFBmbk96MUpvc3ZJc1pJYTU3a0Q0UWJEQTkyY0hTOGJKTXNYdThaQ0VaY0pwVnNRcmdIRXNVRXFOa25tcDRBTkVKVTJieTRjczYwUm53aWZaU21NYVNhOE1JTi1MY00zb00?oc=5","date":"2024-03-20","type":"pipeline","source":"Science | AAAS","summary":"The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis - Science | AAAS","headline":"The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNcVA1N3JlNi1TYjk1LWp3MTg0cG9ZRk9BcE4xeXNSaTV4V20xdnAyeW5NU19ueUpfS1NTZlRBeTRXWTVOVExxbmJmTEZseWhQU1c1MmNKdFBwRlhQNS16WFJPODlMSVZLbkVRYWFOeko4RjhTZEJwNEpfMXpRUUxja0R4TjN4VU1aUlBuNTdwSXBaX1dnUk9RUg?oc=5","date":"2023-08-23","type":"pipeline","source":"The Pharma Letter","summary":"Illuminating spinal muscular atrophy - update 2023 - The Pharma Letter","headline":"Illuminating spinal muscular atrophy - update 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOR1dnSkVyVHpiME9qTmlpdlhqTjhTVUlCY0l1aVBTUXZDODJ4elFYd0pFckVOMDlJRTNhd08tZDdGOTZUT3NhTHJCYUp0Ti1lTHd3U1hfR01CVllYY2xmNEhMNi1oZmlST3hzc0o5ejhsdGROb3ZMbDg2cDhadjJzZ0pNNjUtREQ0R2huNTJn?oc=5","date":"2023-07-08","type":"pipeline","source":"Allied Market Research","summary":"Spinal Muscular Atrophy Treatment Market Size & Share 2032 - Allied Market Research","headline":"Spinal Muscular Atrophy Treatment Market Size & Share 2032","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQNS1tNi1OYUZFUHhGbTE3NEgzbXY1R1JqZDVMSkVfenJxZU5jdWhRTDl6dHRyRnV6YU5DMExiTW9JRm0zUk5PelU3VmNrdjNFNEZHOFJNQ196UEt6NWZDMnNhSDhNUTN4YlJpdW52WHVsc2JKX0RZYzlMX0gtNzRyWGM4MG1GRUU0UE9jSmFJY21MWGs?oc=5","date":"2022-10-11","type":"trial","source":"Labiotech.eu","summary":"Positive results from NMD Pharma myasthenia gravis trial - Labiotech.eu","headline":"Positive results from NMD Pharma myasthenia gravis trial","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}